Blue background

Pipeline and Clinical Trials

Corcept Sponsored Trials

Cushing’s Syndrome

Target Indication (Study Name)
Compound
Phase I
Phase II
Phase III
Phase IV
Target Indication (Study Name)
Endogenous Cushing syndrome (GRACE)
Compound
Relacorilant
Phase III
Target Indication (Study Name)
Hypercortisolism associated with adrenal adenoma or hyperplasia (GRADIENT)
Compound
Relacorilant
Phase III
Target Indication (Study Name)
Extension study to evaluate long term safety
Compound
Relacorilant
Phase II
Target Indication (Study Name)
Prevalence and treatment of Cushing’s syndrome (CATALYST)
Compound
Korlym
Phase IV

Oncology

Target Indication (Study Name)
Compound
Phase I
Phase II
Phase III
Target Indication (Study Name)
Platinum-resistant ovarian cancer (ROSELLA)
Compound
Relacorilant + Abraxane (nab-paclitaxel)
Phase III
Target Indication (Study Name)
Adrenal cancer with cortisol excess
Compound
Relacorilant + Keytruda (pembrolizumab)
Phase I

Neurology

Target Indication (Study Name)
Compound
Phase I
Phase II
Phase III
Target Indication (Study Name)
ALS (DAZALS)
Compound
Dazucorilant
Phase II

Non-Alcoholic Steatohepatitis

Target Indication (Study Name)
Compound
Phase I
Phase II
Phase III
Target Indication (Study Name)
NASH
Compound
Miricorilant
Phase I
Target Indication (Study Name)
NASH (MONARCH)
Compound
Miricorilant
Phase II

Investigator Sponsored Trials

Oncology

Target Indication
Compound
Phase I
Phase II
Phase III
Target Indication
Triple-negative breast cancer
Compound
Mifepristone + Abraxane (nab-paclitaxel)1
Phase II Completed
Target Indication
Prostate cancer
Compound
Relacorilant + Xtandi (enzalutamide)1
Phase II

Addiction

Target Indication
Compound
Phase I
Phase II
Phase III
Target Indication
Alcohol use disorder
Compound
Miricorilant + Behavioral Therapy2
Phase II Completed
Target Indication
Alcohol use disorder
Compound
Mifepristone3
Phase I

Psychiatry

Target Indication
Compound
Phase I
Phase II
Phase III
Target Indication
Alzheimer’s disease
Compound
CORT1082973
Phase II
Target Indication
PTSD
Compound
CORT1082974
Phase II
Target Indication
Major depression
Compound
Mifepristone5
Phase II

Additional Areas of Research

Antipsychotic-induced Weight Gain
Anxiety
Central Serous Chorioretinopathy
Diabetes
Hypertension
Neurodegenerative diseases
Non-alcoholic fatty liver disease
Non-small cell lung cancer
Obesity
Osteoporosis

NASH: non-alcoholic steatohepatitis. ALS: amyotrophic lateral sclerosis. PTSD: post-traumatic stress disorder.

1University of Chicago.
2Scripps Research Institute and the National Institute on Alcohol Abuse and Alcoholism.
3John Hopkins University.

4VA Office of Research and Development.
5Amsterdam UMC.

Corcept's Clinical Trials

View Information on Clinical Trials

Clinical Trials